A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 20 Jan 2017 Planned End Date changed from 1 Jan 2019 to 1 Nov 2018.
- 20 Jan 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Nov 2018.
- 20 Jan 2017 Status changed from recruiting to active, no longer recruiting.